ATE2192T1 - PROCESS FOR PREPARING AN IMMUNOGLOBULIN SOLUTION CONTAINING IGM IN CONCENTRATED FORM FOR INTRAVENOUS APPLICATION. - Google Patents

PROCESS FOR PREPARING AN IMMUNOGLOBULIN SOLUTION CONTAINING IGM IN CONCENTRATED FORM FOR INTRAVENOUS APPLICATION.

Info

Publication number
ATE2192T1
ATE2192T1 AT80100087T AT80100087T ATE2192T1 AT E2192 T1 ATE2192 T1 AT E2192T1 AT 80100087 T AT80100087 T AT 80100087T AT 80100087 T AT80100087 T AT 80100087T AT E2192 T1 ATE2192 T1 AT E2192T1
Authority
AT
Austria
Prior art keywords
igm
propiolactone
beta
solution
treatment
Prior art date
Application number
AT80100087T
Other languages
German (de)
Inventor
Wolfgang Dr.-Dipl.-Chem. Stephan
Original Assignee
Biotest-Serum-Institut Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest-Serum-Institut Gmbh filed Critical Biotest-Serum-Institut Gmbh
Application granted granted Critical
Publication of ATE2192T1 publication Critical patent/ATE2192T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/806Drug, bio-affecting and body treating compositions involving IgM
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • Y10S530/83Plasma; serum
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • Y10S530/83Plasma; serum
    • Y10S530/831Cohn fractions
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/832Milk; colostrum
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A process for the preparation of an immunoglobulin solution containing IgM in concentrated form and suited for intravenous administration, comprising treating an IgM-containing protein fraction obtained by conventional fractionation from blood plasma or serum with beta -propiolactone in an amount such that the ratio of beta -propiolactone to a 5% solution of the IgM-containing proteins is from about 0.05 to 0.15 ml per 100 ml. Advantageously, prior to the treatment with beta -propiolactone the IgM-containing protein fraction is freed of lipids by treatment with colloidal silica gel and with crosslinked dextrans or diethylaminoethyl cellulose. The starting material used is a Cohn fraction III of human blood plasma which has been dissolved in physiological saline solution to a concentration of about 5% protein, the treatment with beta -propiolactone is carried out at about 20 DEG to 37 DEG C. for about 4 to 6 hours until a substantially constant pH of about 8 is obtained, and the solution is thereafter sterile filtered.
AT80100087T 1979-01-18 1980-01-09 PROCESS FOR PREPARING AN IMMUNOGLOBULIN SOLUTION CONTAINING IGM IN CONCENTRATED FORM FOR INTRAVENOUS APPLICATION. ATE2192T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19792901822 DE2901822A1 (en) 1979-01-18 1979-01-18 METHOD FOR THE PRODUCTION OF AN IMMUNOGLOBULIN SOLUTION SUITABLE FOR THE INTRAVENOUS APPLICATION THAT IGM CONTAINS IN A CONCENTRATED FORM
EP80100087A EP0013901B1 (en) 1979-01-18 1980-01-09 Process of preparation of an intravenous immunoglobulin solution, containing concentrated igm

Publications (1)

Publication Number Publication Date
ATE2192T1 true ATE2192T1 (en) 1983-01-15

Family

ID=6060836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT80100087T ATE2192T1 (en) 1979-01-18 1980-01-09 PROCESS FOR PREPARING AN IMMUNOGLOBULIN SOLUTION CONTAINING IGM IN CONCENTRATED FORM FOR INTRAVENOUS APPLICATION.

Country Status (4)

Country Link
US (1) US4318902A (en)
EP (1) EP0013901B1 (en)
AT (1) ATE2192T1 (en)
DE (2) DE2901822A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033932C2 (en) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the cold sterilization of preparations containing blood coagulation factor VIII
US4775638A (en) * 1985-05-08 1988-10-04 Centocor, Inc. Single vial technique for radiolabeling protein
JPH0662436B2 (en) * 1986-05-19 1994-08-17 株式会社ミドリ十字 Method for producing intravenous immunoglobulin preparation
DE3640513A1 (en) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh METHOD FOR THE PRODUCTION OF A VIRUS-SAFE, STORAGE-STABLE AND INTRAVENOES COMPATIBLE IMMUNGLOBULIN-G-PRAEPARATES
DE3641115A1 (en) * 1986-12-02 1988-06-16 Lentia Gmbh METHOD FOR PRODUCING AN INTRAVENOUS APPLICABLE AND STABLE IN LIQUID FORM IMMUNOGLOBULINS
US4841026A (en) * 1987-01-27 1989-06-20 Miles Laboratories, Inc. Virally inactivated, non-toxic, human transferrin preparation
US5157113A (en) * 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
DE3825429C2 (en) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Method for producing an intravenously administrable polyclonal immunoglobulin preparation with a high IgM content
DE3927111C3 (en) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Process for the preparation of unmodified intravenous IgM and / or IgA-containing immunoglobulin preparations
DE3927112C1 (en) * 1989-08-17 1990-10-25 Biotest Pharma Gmbh, 6072 Dreieich, De
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
EP0835880A1 (en) * 1996-10-14 1998-04-15 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Process for producing an IgM preparation for intravenous administration
CA2232420A1 (en) * 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
DE102007001521A1 (en) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Use of Cohn-Oncley fractions II and II / III for the treatment of systemic lupus erythematosus
GB201006753D0 (en) * 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
RU2470664C2 (en) * 2010-08-23 2012-12-27 Андрей Германович Лютов Method for producing immunoglobulin for intravenous introduction of immunoglobulin m enriched preparation, and preparation prepared by such method
RU2735680C2 (en) 2016-03-14 2020-11-05 Биотест Аг Treatment of severe community-acquired pneumonia
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111000253A (en) * 2019-12-03 2020-04-14 武汉跃莱健康产业有限公司 Composite polypeptide protein powder and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872122A (en) 1958-06-13 1961-07-05 Joos Bernhard Stabilizing sera
NL240154A (en) 1959-06-12
DE1792555C3 (en) * 1968-09-19 1980-01-10 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the preparation of a gamma globulin solution suitable for intravenous use
US3597409A (en) * 1970-05-25 1971-08-03 American Cyanamid Co Process for recoverring immunoglobulin a and immunoglobulin m

Also Published As

Publication number Publication date
US4318902A (en) 1982-03-09
DE3061547D1 (en) 1983-02-17
EP0013901B1 (en) 1983-01-12
EP0013901A1 (en) 1980-08-06
DE2901822A1 (en) 1980-07-31

Similar Documents

Publication Publication Date Title
ATE2192T1 (en) PROCESS FOR PREPARING AN IMMUNOGLOBULIN SOLUTION CONTAINING IGM IN CONCENTRATED FORM FOR INTRAVENOUS APPLICATION.
AU621148B2 (en) Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
DE2801123C2 (en) Process for the production of a serum protein preparation which can be administered intravenously
DE69019074T2 (en) Process for the fractionation of plasma proteins.
US4081431A (en) Blood fractionation
DE2548636A1 (en) ANTISERIC AND ANTIBODIES WITH SPECIFIC EFFECT AGAINST CANCER CELL PROTEINS, THE PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS
ATE62816T1 (en) PROCESS FOR MANUFACTURING HIGHLY PURIFIED, ELECTRICITY-FREE, HEPATITIS-SAFE HUMAN AND ANIMAL HEMOGLOBIN SOLUTIONS.
US3916026A (en) Method for the preparation of gamma-globulin suitable for intravenous use
DE3228502A1 (en) METHOD FOR PRODUCING THE C1 INACTIVATOR AND ITS USE
US4082734A (en) Production of intravenously applicable native human immune globulin having a normal half-life
US4301064A (en) Ubiquitary tissue protein PP8
DE59008883D1 (en) Process for the preparation of unmodified intravenous IgM and / or IgA-containing immunoglobulin preparations.
EP0127603B1 (en) Process for the preparation of a composition containing a factor viii(ahf)
JP2965623B2 (en) Method for producing purified albumin solution
US4017470A (en) Method for preparing a heat-stable plasma protein solution from paste IV-1
US4322403A (en) Method for the preparation of an immune globulin solution suitable for intravenous use
JPS6160817B2 (en)
DE3330770A1 (en) METHOD FOR PASTEURIZING HUMAN PLASMA
US4312949A (en) Method for the preparation of a gamma globulin solution suitable for intravenous use
DE2742150A1 (en) METHOD FOR MANUFACTURING SERUM ALBUMIN
US2123198A (en) Treatment of antitoxins and the like
RU2019190C1 (en) Method of monospecific antiserum preparing
DE2757084A1 (en) SOFT CONTACT LENS AND THEIR MANUFACTURING METHOD
CH646439A5 (en) Preparation of albumin from plasma
DE2415079B2 (en) Method for isolating albumin from blood plasma